CHFR and cancer: The wealth of functional and preclinical data about the role of CHFR in the control of the mitotic checkpoint, as well as the clinical data showing improved response and survival following taxane based therapy in patients with reduced or epigenetically silenced CHFR expression firmly establish CHFR as a promising molecular target in cancer.